Market Cap
$8.6M
LGVN
Longeveron Inc.
$2.61 ▲ +0.77%
Prev close $2.59Market cap$8.6M
12-mo target$61.25 (+2246.7%)
High Impact Filing (7/10)4 New Institutional Positions Biotech & Drug Discovery
Snapshot
The big-picture read on LGVN right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Inst. Holders
21 funds
Inst. Value
$2.2M
Inst. Activity
4 buys / 1 sells
Social Sentiment
67° Warm
SEC Reports
9
Press Releases
3
Price chart 30d -61.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 other
Sep 14, 2026 SEC Longeveron to Participate in Three Longevity/Aging Investment Conferences
Longeveron (LGVN) to participate in three upcoming Longevity/Aging investment conferences.
Longeveron received written notification from Nasdaq on September 11, 2026, confirming that its Class A common stock had
8-K — Impact 5/10
Aug 19, 2026 Insider
Ascheim Deborah was granted 36,000 shares
Director
Aug 19, 2026 Insider
Agafonova Nataliya was granted 286,000 shares
Chief Medical Officer
Aug 19, 2026 Insider
Jul 13, 2026 SEC Lehr Paul T was granted 286,000 shares
General Counsel, Secretary
Two new insiders (Leah Rush Cann and Deborah Ascheim) filed initial beneficial ownership statements on Form 3, each repo
3 — Impact 2/10
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — DOUBLED
1,353,881 shares ($951.8K)
Jun 30, 2026 Inst.
VANGUARD FIDUCIARY TRUST CO — DOUBLED
140,127 shares ($98.5K)
Analyst ratings buy % -11.4%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| May 11, 2026 | Maxim Group | DOWNGRADE | Hold | 43% |
| May 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Aug 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Jul 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Jun 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Price targets
Where 2 covering analysts think LGVN trades over the next 12 months.
$61.25 +2246.7% upside Strong Buy
Current$2.61 Low$42.50 Median$61.25 High$80.00 2 analysts
$42.50$80.00
Analyst rating Buy· 2.0/5 as of Oct 2, 2026
Social media sentiment mood +20.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
67°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 1 bullish, 4 bearish, 0 mixed, 4 neutral · avg impact 4.8/10.Plus 3 press releases.
BULLISH8-K5/10
Longeveron received written notification from Nasdaq on September 11, 2026, confirming that its Clas
Sep 14, 2026
NEUTRAL32/10
Two new insiders (Leah Rush Cann and Deborah Ascheim) filed initial beneficial ownership statements
Jul 13, 2026
NEUTRAL8-K4/10
CFO Lisa Locklear is stepping down effective July 10, 2026, with controller Marie Washburn expected
Jun 5, 2026
NEUTRAL8-K3/10
Longeveron reported Q1 2026 results in line with consensus: EPS -$0.19 matched Street estimates and
May 13, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 30, 2026
other
Longeveron to Participate in Three Longevity/Aging Investment Conferences
Longeveron (LGVN) to participate in three upcoming Longevity/Aging investment conferences.
Sep 16, 2026
trading_halt
Halt Resumed: LGVN — trading resumed after T3 (News and Resumption Times)
Halted 2026-09-16T20:55:00.000Z | Resumed 2026-09-16T21:55:00.000Z
Sep 16, 2026
fda
Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for HLHS
Sep 16, 2026
trading_halt
Trading Halt: LGVN — T1 (News Pending)
Longeveron Inc. Class A Cmn | Market: NASDAQ | Code: T1 — News Pending
Sep 16, 2026
trading_halt
Trading Halt: LGVN — T2 (News Released)
Longeveron Inc. Class A Cmn | Market: NASDAQ | Code: T2 — News Released
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.93 | $-2.20–$-1.70 | 50.4% | -13.7% | 0↑ 1↓ | $0.0B | 3 |
| Next Q | $-1.77 | $-1.80–$-1.70 | 19.7% | -12.2% | 1↑ 1↓ | $0.0B | 3 |
| Current FY | $-7.63 | $-8.30–$-7.20 | 40.8% | -6.0% | 1↑ 1↓ | $0.0B | 3 |
| Next FY | $-4.93 | $-5.80–$-4.20 | 35.4% | -5.0% | 1↑ 2↓ | $0.0B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.933 | — |
| 7d ago | $-1.700 | -0.233 |
| 30d ago | $-1.700 | -0.233 |
| 60d ago | $-1.500 | -0.433 |
| 90d ago | $-1.500 | -0.433 |
Institutional ownership
Which big funds own LGVN (from quarterly 13F filings) and who is adding or trimming.
21 institutional holders with $2.2M total value (3,067,525 shares) as of 2026-Q2. Top holders: MILLENNIUM, VANGUARD, BlackRock,. Net buying activity: 4 institutions added/increased vs 1 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | 1,353,881 | $951.8K | 44.1% | DOUBLED +203.1% |
| VANGUARD CAPITAL MANAGEMENT LLC | 581,305 | $408.7K | 19.0% | — |
| BlackRock, Inc. | 224,170 | $157.6K | 7.3% | DOUBLED +2138.4% |
| GEODE CAPITAL MANAGEMENT, LLC | 203,761 | $143.2K | 6.6% | ADD +43.9% |
| JANE STREET GROUP, LLC | 190,370 | $133.8K | 6.2% | — |
| VANGUARD FIDUCIARY TRUST CO | 140,127 | $98.5K | 4.6% | DOUBLED +261.9% |
| Mariner, LLC | 126,000 | $88.6K | 4.1% | — |
| Beacon Pointe Advisors, LLC | 100,000 | $70.3K | 3.3% | — |
| NORTHERN TRUST CORP | 43,299 | $30.4K | 1.4% | DOUBLED +118.9% |
| SCOTIA CAPITAL INC. | 30,000 | $21.1K | 1.0% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | DOUBLED | 446,725 | 1,353,881 | +203.1% | $951.8K |
| VANGUARD FIDUCIARY TRUST CO | DOUBLED | 38,715 | 140,127 | +261.9% | $98.5K |
| NORTHERN TRUST CORP | DOUBLED | 19,779 | 43,299 | +118.9% | $30.4K |
| JONES FINANCIAL COMPANIES LLLP | DOUBLED | 300 | 1,300 | +333.3% | $930.00 |
| UBS Group AG | NEAR_EXIT | 14,862 | 5 | -100.0% | $4.00 |
| BlackRock, Inc. | DOUBLED | 10,016 | 224,198 | +2138.4% | $233.2K |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 141,501 | 203,618 | +43.9% | $211.8K |
| NORTHERN TRUST CORP | TRIM | 48,404 | 19,779 | -59.1% | $20.6K |
| UBS Group AG | NEAR_EXIT | 60,208 | 14,862 | -75.3% | $15.5K |
| HRT FINANCIAL LP | DOUBLED | 11,989 | 118,891 | +891.7% | $123.00 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
14 insiders, 32 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | Ascheim Deborah | Director | AWARD | 36,000 | — | — |
| Aug 19, 2026 | Agafonova Nataliya | Chief Medical Officer | AWARD | 286,000 | — | — |
| Aug 19, 2026 | Lehr Paul T | General Counsel, Secretary | AWARD | 286,000 | — | — |
| Aug 19, 2026 | Soffer Rock | Director | AWARD | 36,000 | — | — |
| Aug 19, 2026 | Desai Arjun JJ | Director | AWARD | 36,000 | — | — |
| Aug 19, 2026 | Cann Leah Rush | Director | AWARD | 36,000 | — | — |
| Aug 19, 2026 | Blass Devin | CTO & SVP of CMC | AWARD | 286,000 | — | — |
| Aug 19, 2026 | Hajjar Roger Joseph | Director | AWARD | 36,000 | — | — |
| Aug 19, 2026 | Ungaro Ursula | Director | AWARD | 36,000 | — | — |
| Aug 19, 2026 | Paletta George A. Jr. | Director | AWARD | 36,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for LGVN.
Shares short
213,777
Settlement Sep 15, 2026
Change vs prior
-5.5%
Semi-monthly cycle
Days to cover
4.7
At avg daily volume
Of shares outstanding
≈6.7%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Sep 16, 2026 | T1 | News Pending | Not resumed |
| Sep 16, 2026 | T2 | News Released | Not resumed |
| Sep 16, 2026 | T3 | Resumption Scheduled | Resumed |
| Aug 26, 2026 | T1 | News Pending | Not resumed |
| Aug 26, 2026 | T3 | Resumption Scheduled | Resumed |
All LGVN filing & press-release reports (12)
- 8-K reportSep 14, 2026
- 3 reportJul 13, 2026
- 8-K reportJun 5, 2026
- PRESS-RELEASE reportMay 20, 2026
- 8-K reportMay 13, 2026
- 8-K reportMay 8, 2026
- EFFECT reportApr 20, 2026
- 8-K reportApr 10, 2026
- S-1 reportApr 10, 2026
- PRESS-RELEASE reportMar 17, 2026
- PRESS-RELEASE reportMar 11, 2026
- 8-K reportMar 9, 2026